Enliven Therapeutics

About Enliven Therapeutics

Enliven Therapeutics, Inc. (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company headquartered in Boulder, Colorado, that specializes in the discovery and development of small molecule kinase inhibitors for oncology. The company's business model is centered on advancing its pipeline of precision oncology therapies through clinical trials, with the ultimate goal of commercialization and addressing unmet needs in cancer treatment. As a clinical-stage entity, Enliven does not currently generate revenue from product sales; its operations are financed through equity offerings and investments. The company has successfully raised significant capital, including a $90 million PIPE financing in March 2024 and a public offering of approximately $230 million in June 2025, to fund its research and development activities. This financial strategy is designed to provide a cash runway to support operations and key clinical milestones into late 2027.

Founded on June 1, 2019, by Sam Kintz, Joe Lyssikatos, and Anish Patel, the company emerged from stealth mode in December 2020 with a mission to help cancer patients live longer and better lives. The founders bring extensive experience from leadership roles at prominent pharmaceutical and biotech companies such as AbbVie, Genentech, Biogen, and Pharmacyclics. Sam Kintz, the CEO, previously held positions at AbbVie Stemcentrx and the Roche Venture Fund. Joe Lyssikatos, the Chief Scientific Officer, has a background in medicinal chemistry at companies including Biogen, AbbVie, and Pfizer. Anish Patel, the Chief Operating Officer, contributed to the commercialization of Imbruvica® at Pharmacyclics. A significant milestone was the company's merger with Imara Inc. in February 2023, which resulted in Enliven becoming a publicly traded company on Nasdaq under the ticker ELVN.

Enliven's therapeutic approach focuses on designing potentially best-in-class or first-in-class therapies by combining insights into clinically validated biological targets with differentiated chemistry. The company's pipeline targets cancers that are treated with suboptimal drugs, aiming to improve tolerability, overcome resistance, and address issues like brain metastases. The lead product candidate, ELVN-001, is a potent and highly selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion, the primary driver of chronic myeloid leukemia (CML). ELVN-001 has shown a favorable safety and tolerability profile in its Phase 1 clinical trial and has received Orphan Drug Designation from the U.S. FDA for the treatment of CML. The second lead candidate, ELVN-002, is a central nervous system (CNS) penetrant and irreversible HER2 inhibitor designed to treat solid tumors with HER2 alterations, such as those in breast, colorectal, and non-small cell lung cancer, while avoiding certain toxicities associated with other inhibitors. The company is preparing for a potential pivotal trial for ELVN-001 to start in 2026.